

Sample **MOLLY - G - WATERMELON**

Delta9 THC ND

THCa ND

Total THC (THCa * 0.877 + THC) ND

Delta8 THC <LOQ



Sample ID	SD251029-108 (126406)	Matrix	Edible
Tested for	MOLLY		
Sampled	-	Received	Oct 29, 2025
Analyses executed	CANX, 4AD, TRY, PSY	Unit Mass (g)	12.007
		Reported	Nov 04, 2025
		Num. of Servings	3
		Serving Size (g)	4.0

CANx - Cannabinoids

Analyzed Oct 30, 2025 | Instrument HPLC-VWD | Method SOP-001
The expanded Uncertainty of the Cannabinoids analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
11-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND	ND	ND
Cannabidiol (CBDO)	0.006	0.02	ND	ND	ND	ND
Abnormal Cannabidiol (a-CBDO)	0.013	0.038	ND	ND	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND	ND
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.015	0.045	ND	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND	ND
Cannabidiol (CBD)	0.069	0.229	<LOQ	<LOQ	<LOQ	<LOQ
1(S)-Tetrahydrocannabidiol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND	ND
1(R)-Tetrahydrocannabidiol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND	ND
Tetrahydrocannabivarin (THCV)	0.049	0.162	ND	ND	ND	ND
Δ8-tetrahydrocannabivarin (Δ8-THCV)	0.012	0.036	ND	ND	ND	ND
Cannabidihexol (CBDH)	0.014	0.042	ND	ND	ND	ND
Tetrahydrocannabutol (Δ9-THCB)	0.01	0.029	ND	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	<LOQ	<LOQ	<LOQ	<LOQ
Cannabidiphorol (CBDP)	0.016	0.049	ND	ND	ND	ND
exo-THC (exo-THC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.092	0.307	ND	ND	ND	ND
Δ8-tetrahydrocannabinol (Δ8-THC)	0.044	0.16	<LOQ	<LOQ	<LOQ	<LOQ
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.8	ND	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	ND	ND	ND	ND
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.8	ND	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	ND	ND	ND	ND
Δ9-Tetrahydrocannabihexol (Δ9-THCH)	0.02	0.061	ND	ND	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND	ND
9(S)-Hexahydrocannabinolic Acid (9(S)-HHCa)	0.063	0.065	ND	ND	ND	ND
9(R)-Hexahydrocannabinolic Acid (9(R)-HHCa)	0.191	0.196	ND	ND	ND	ND
Δ9-Tetrahydrocannabiphorol (Δ9-THCP)	0.017	0.8	ND	ND	ND	ND
Δ8-Tetrahydrocannabiphorol (Δ8-THCP)	0.041	0.8	ND	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND	ND
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.8	ND	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND	ND	ND
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.8	ND	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.015	0.045	ND	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.021	0.062	ND	ND	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			ND	ND	ND	ND
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			ND	ND	ND	ND
Total CBD (CBDa * 0.877 + CBD)			ND	ND	ND	ND
Total CBG (CBGa * 0.877 + CBG)			ND	ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND	ND
Total Cannabinoids Analyzed			ND	ND	ND	ND

4AD - 4AD Tryptamines

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-4AD
The expanded Uncertainty of the 4AD Tryptamines analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Mescaline (MESC)	0.19	0.584	ND	ND	ND	ND
N-methyl Tryptamine (NMT)	0.004	0.013	ND	ND	ND	ND
4-Hydroxy-MET (4-HO-MET)	0.013	0.04	ND	ND	ND	ND
n,n Dimethyltryptamine (DMT)	0.015	0.048	ND	ND	ND	ND
Psilacetin (PSLA)	0.015	0.044	ND	ND	ND	ND
4-Hydroxy-DET (4-HO-DET)	0.014	0.042	ND	ND	ND	ND

4-Acetoxy-MET (4-AcO-MET)	0.018	0.053	ND	ND	ND	ND
4-Acetoxy-DET (4-AcO-DET)	0.004	0.011	ND	ND	ND	ND
4-Bromo-DMP (2C-B)	0.19	0.576	ND	ND	ND	ND

TRY - Tryptamine

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-TRY
The expanded Uncertainty of the Tryptamine analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Norbaeocystin (NORB)	0.01	0.029	ND	ND	ND	ND
Baeocystin (BAEO)	0.01	0.029	ND	ND	ND	ND
Aeruginascin (AERU)	0.007	0.022	ND	ND	ND	ND
Norpsilocin (NORP)	0.003	0.009	ND	ND	ND	ND

PSY - Psilocybin & Psilocin

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-PSY
The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Psilocybin (PSCY)	0.007	0.019	ND	ND	ND	ND
Psilocin (PSCI)	0.003	0.009	ND	ND	ND	ND

UI Unidentified
ND Not Detected
N/A Not Applicable
NT Not Reported
LOD Limit of Detection
LOQ Limit of Quantification
<LOQ Detected
>ULOL Above upper limit of linearity
CFU/g Colony Forming Units per 1 gram
TNTC Too Numerous to Count



Coa_pjla_testing
(http://www.pjllabs.com)
Acc. #85368
(https://www.dropbox.com/scl/fi/3qeqn2se34ulpw8lm13ui/85368.pdf?rlkey=nviqubdnfhk1v1f6rx32mew63u&st=8wa4rbwv&dl=0)

DEA license: RP0611043
ISO/IEC 17025:2017 Acc.
85368



Scan the QR code to
verify.



Authorized Signature
Brandon_starr
Brandon Starr, Quality Assurance Manager
Tue, 04 Nov 2025 07:42:17 -0800



Pharmware_logo_simp
(https://pharmware.net)

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368

PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.

Sample **MOLLY - G - VERY BERRY**

Delta9 THC <LOQ	THCa ND	Total THC (THCa * 0.877 + THC) <LOQ	Delta8 THC ND
--------------------	------------	--	------------------



Sample ID	SD251029-107 (126405)	Matrix	Edible
Tested for	MOLLY		
Sampled	-	Received	Oct 29, 2025
Reported	Nov 04, 2025		
Analyses executed	CANX, 4AD, TRY, PSY	Unit Mass (g)	11.982
		Num. of Servings	3
		Serving Size (g)	3.99

CANx - Cannabinoids

Analyzed Oct 30, 2025 | Instrument HPLC-VWD | Method SOP-001
The expanded Uncertainty of the Cannabinoids analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
11-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND	ND	ND
Cannabidiol (CBDO)	0.006	0.02	ND	ND	ND	ND
Abnormal Cannabidiol (a-CBDO)	0.013	0.038	ND	ND	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND	ND
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.015	0.045	ND	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND	ND
Cannabidiol (CBD)	0.069	0.229	ND	ND	ND	ND
1(S)-Tetrahydrocannabidiol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND	ND
1(R)-Tetrahydrocannabidiol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND	ND
Tetrahydrocannabivarin (THCV)	0.049	0.162	ND	ND	ND	ND
Δ8-tetrahydrocannabivarin (Δ8-THCV)	0.012	0.036	ND	ND	ND	ND
Cannabidiol (CBDH)	0.014	0.042	ND	ND	ND	ND
Tetrahydrocannabutol (Δ9-THCB)	0.01	0.029	ND	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	<LOQ	<LOQ	<LOQ	<LOQ
Cannabidiophorol (CBDP)	0.016	0.049	ND	ND	ND	ND
exo-THC (exo-THC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.092	0.307	<LOQ	<LOQ	<LOQ	<LOQ
Δ8-tetrahydrocannabinol (Δ8-THC)	0.044	0.16	ND	ND	ND	ND
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.8	ND	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	ND	ND	ND	ND
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.8	ND	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	ND	ND	ND	ND
Δ9-Tetrahydrocannabihexol (Δ9-THCH)	0.02	0.061	ND	ND	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND	ND
9(S)-Hexahydrocannabinolic Acid (9(S)-HHCa)	0.063	0.065	ND	ND	ND	ND
9(R)-Hexahydrocannabinolic Acid (9(R)-HHCa)	0.191	0.196	ND	ND	ND	ND
Δ9-Tetrahydrocannabiphorol (Δ9-THCP)	0.017	0.8	ND	ND	ND	ND
Δ8-Tetrahydrocannabiphorol (Δ8-THCP)	0.041	0.8	ND	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND	ND
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.8	ND	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND	ND	ND
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.8	ND	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.015	0.045	ND	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.021	0.062	ND	ND	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			ND	ND	ND	ND
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			ND	ND	ND	ND
Total CBD (CBDa * 0.877 + CBD)			ND	ND	ND	ND
Total CBG (CBGa * 0.877 + CBG)			ND	ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND	ND
Total Cannabinoids Analyzed			ND	ND	ND	ND

4AD - 4AD Tryptamines

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-4AD
The expanded Uncertainty of the 4AD Tryptamines analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Mescaline (MESc)	0.19	0.584	ND	ND	ND	ND
N-methyl Tryptamine (NMT)	0.004	0.013	ND	ND	ND	ND
4-Hydroxy-MET (4-HO-MET)	0.013	0.04	ND	ND	ND	ND
n,n Dimethyltryptamine (DMT)	0.015	0.048	ND	ND	ND	ND
Psilacetin (PSLA)	0.015	0.044	ND	ND	ND	ND
4-Hydroxy-DET (4-HO-DET)	0.014	0.042	ND	ND	ND	ND

4-Acetoxy-MET (4-AcO-MET)	0.018	0.053	ND	ND	ND	ND
4-Acetoxy-DET (4-AcO-DET)	0.004	0.011	ND	ND	ND	ND
4-Bromo-DMP (2C-B)	0.19	0.576	ND	ND	ND	ND

TRY - Tryptamine

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-TRY
The expanded Uncertainty of the Tryptamine analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Norbaeocystin (NORB)	0.01	0.029	ND	ND	ND	ND
Baeocystin (BAEO)	0.01	0.029	ND	ND	ND	ND
Aeruginascin (AERU)	0.007	0.022	ND	ND	ND	ND
Norpsilocin (NORP)	0.003	0.009	ND	ND	ND	ND

PSY - Psilocybin & Psilocin

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-PSY
The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Psilocybin (PSCY)	0.007	0.019	ND	ND	ND	ND
Psilocin (PSCI)	0.003	0.009	ND	ND	ND	ND

UI Unidentified
ND Not Detected
N/A Not Applicable
NT Not Reported
LOD Limit of Detection
LOQ Limit of Quantification
<LOQ Detected
>ULOL Above upper limit of linearity
CFU/g Colony Forming Units per 1 gram
TNTC Too Numerous to Count



Coa_pjla_testing
(http://www.pjlab.com)
Acc. #85368
(https://www.dropbox.com/scl/fi/3qeqn2se34ulpw8lm13ui/85368.pdf?rlkey=nviqubdnfhk1v1f6rx32mew63u&st=8wa4rbwv&dl=0)

DEA license: RP0611043
ISO/IEC 17025:2017 Acc.
85368



Scan the QR code to
verify.



Authorized Signature
Brandon_starr
Brandon Starr, Quality Assurance Manager
Tue, 04 Nov 2025 07:42:03 -0800



Pharmware_logo_simp
(https://pharmware.net)

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368

PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.

Sample **MOLLY - G - PUPLE PUNCH**

Delta9 THC **ND**

THCa **ND**

Total THC (THCa * 0.877 + THC) **ND**

Delta8 THC **<LOQ**



Sample ID SD251029-106 (126404)				Matrix Edible	
Tested for MOLLY					
Sampled -		Received Oct 29, 2025		Reported Nov 04, 2025	
Analyses executed CANX, 4AD, TRY, PSY		Unit Mass (g) 11.959		Num. of Servings 3	
				Serving Size (g) 3.99	

CANx - Cannabinoids

Analyzed **Oct 30, 2025** | Instrument **HPLC-VWD** | Method **SOP-001**
The expanded Uncertainty of the Cannabinoids analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
11-Hydroxy- Δ 8-Tetrahydrocannabivarin (11-Hyd- Δ 8-THCV)	0.013	0.041	ND	ND	ND	ND
Cannabidiol (CBDO)	0.006	0.02	ND	ND	ND	ND
Abnormal Cannabidiol (a-CBDO)	0.013	0.038	ND	ND	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND	ND
11-Hydroxy- Δ 8-Tetrahydrocannabinol (11-Hyd- Δ 8-THC)	0.015	0.045	ND	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND	ND
Cannabidiol (CBD)	0.069	0.229	<LOQ	<LOQ	<LOQ	<LOQ
1(S)-Tetrahydrocannabidiol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND	ND
1(R)-Tetrahydrocannabidiol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND	ND
Tetrahydrocannabivarin (THCV)	0.049	0.162	ND	ND	ND	ND
Δ 8-tetrahydrocannabivarin (Δ 8-THCV)	0.012	0.036	ND	ND	ND	ND
Cannabidihexol (CBDH)	0.014	0.042	ND	ND	ND	ND
Tetrahydrocannabutol (Δ 9-THCB)	0.01	0.029	ND	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	<LOQ	<LOQ	<LOQ	<LOQ
Cannabidiphorol (CBDP)	0.016	0.049	ND	ND	ND	ND
exo-THC (exo-THC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinol (Δ 9-THC)	0.092	0.307	ND	ND	ND	ND
Δ 8-tetrahydrocannabinol (Δ 8-THC)	0.044	0.16	<LOQ	<LOQ	<LOQ	<LOQ
(6aR,9S)- Δ 10-Tetrahydrocannabinol ((6aR,9S)- Δ 10)	0.015	0.8	ND	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	ND	ND	ND	ND
(6aR,9R)- Δ 10-Tetrahydrocannabinol ((6aR,9R)- Δ 10)	0.007	0.8	ND	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	ND	ND	ND	ND
Δ 9-Tetrahydrocannabihexol (Δ 9-THCH)	0.02	0.061	ND	ND	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND	ND
9(S)-Hexahydrocannabinolic Acid (9(S)-HHCa)	0.063	0.065	ND	ND	ND	ND
9(R)-Hexahydrocannabinolic Acid (9(R)-HHCa)	0.191	0.196	ND	ND	ND	ND
Δ 9-Tetrahydrocannabiphorol (Δ 9-THCP)	0.017	0.8	ND	ND	ND	ND
Δ 8-Tetrahydrocannabiphorol (Δ 8-THCP)	0.041	0.8	ND	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND	ND
Δ 8-THC-O-acetate (Δ 8-THCO)	0.076	0.8	ND	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND	ND	ND
Δ 9-THC-O-acetate (Δ 9-THCO)	0.066	0.8	ND	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.015	0.045	ND	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND	ND	ND
3-octyl- Δ 8-Tetrahydrocannabinol (Δ 8-THC-C8)	0.021	0.062	ND	ND	ND	ND
Total THC (THCa * 0.877 + Δ 9THC)			ND	ND	ND	ND
Total THC + Δ 8THC + Δ 10THC (THCa * 0.877 + Δ 9THC + Δ 8THC + Δ 10THC)			ND	ND	ND	ND
Total CBD (CBDa * 0.877 + CBD)			ND	ND	ND	ND
Total CBG (CBGa * 0.877 + CBG)			ND	ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND	ND
Total Cannabinoids Analyzed			ND	ND	ND	ND

4AD - 4AD Tryptamines

Analyzed **Oct 30, 2025** | Instrument **HPLC VWD** | Method **SOP-4AD**
The expanded Uncertainty of the 4AD Tryptamines analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Mescaline (MESC)	0.19	0.584	ND	ND	ND	ND
N-methyl Tryptamine (NMT)	0.004	0.013	ND	ND	ND	ND
4-Hydroxy-MET (4-HO-MET)	0.013	0.04	ND	ND	ND	ND
n,n Dimethyltryptamine (DMT)	0.015	0.048	ND	ND	ND	ND
Psilacetin (PSLA)	0.015	0.044	ND	ND	ND	ND
4-Hydroxy-DET (4-HO-DET)	0.014	0.042	ND	ND	ND	ND

4-Acetoxy-MET (4-AcO-MET)	0.018	0.053	ND	ND	ND	ND
4-Acetoxy-DET (4-AcO-DET)	0.004	0.011	ND	ND	ND	ND
4-Bromo-DMP (2C-B)	0.19	0.576	ND	ND	ND	ND

TRY - Tryptamine

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-TRY
The expanded Uncertainty of the Tryptamine analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Norbaeocystin (NORB)	0.01	0.029	ND	ND	ND	ND
Baeocystin (BAEO)	0.01	0.029	ND	ND	ND	ND
Aeruginascin (AERU)	0.007	0.022	ND	ND	ND	ND
Norpsilocin (NORP)	0.003	0.009	ND	ND	ND	ND

PSY - Psilocybin & Psilocin

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-PSY
The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Psilocybin (PSCY)	0.007	0.019	ND	ND	ND	ND
Psilocin (PSCI)	0.003	0.009	ND	ND	ND	ND

UI Unidentified
ND Not Detected
N/A Not Applicable
NT Not Reported
LOD Limit of Detection
LOQ Limit of Quantification
<LOQ Detected
>ULOL Above upper limit of linearity
CFU/g Colony Forming Units per 1 gram
TNTC Too Numerous to Count



Coa_pjla_testing
(http://www.pjllabs.com)
Acc. #85368
(https://www.dropbox.com/scl/fi/3qeqn2se34ulpw8lm13ui/85368.pdf?rlkey=nviqubdnfhk1v1f6rx32mew63u&st=8wa4rbwv&dl=0)

DEA license: RP0611043
ISO/IEC 17025:2017 Acc.
85368



Scan the QR code to
verify.



Authorized Signature
Brandon_starr
Brandon Starr, Quality Assurance Manager
Tue, 04 Nov 2025 07:42:01 -0800



Pharmware_logo_simp
(https://pharmware.net)

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368

PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.

Sample **MOLLY - G - GUAVA**

Delta9 THC ND	THCa <LOQ	Total THC (THCa * 0.877 + THC) <LOQ	Delta8 THC <LOQ
------------------	--------------	--	--------------------



Sample ID	SD251029-105 (126403)	Matrix	Edible
Tested for	MOLLY		
Sampled	-	Received	Oct 29, 2025
		Reported	Nov 04, 2025
Analyses executed	CANX, 4AD, TRY, PSY	Unit Mass (g)	11.983
		Num. of Servings	3
		Serving Size (g)	3.99

CANx - Cannabinoids

Analyzed Oct 30, 2025 | Instrument HPLC-VWD | Method SOP-001
The expanded Uncertainty of the Cannabinoids analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
11-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND	ND	ND
Cannabidiolcin (CBDO)	0.006	0.02	ND	ND	ND	ND
Abnormal Cannabidiolcin (a-CBDO)	0.013	0.038	ND	ND	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND	ND
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.015	0.045	ND	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND	ND
Cannabidiol (CBD)	0.069	0.229	<LOQ	<LOQ	<LOQ	<LOQ
1(S)-Tetrahydrocannabidiol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND	ND
1(R)-Tetrahydrocannabidiol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND	ND
Tetrahydrocannabivarin (THCV)	0.049	0.162	ND	ND	ND	ND
Δ8-tetrahydrocannabivarin (Δ8-THCV)	0.012	0.036	ND	ND	ND	ND
Cannabidihexol (CBDH)	0.014	0.042	ND	ND	ND	ND
Tetrahydrocannabutol (Δ9-THCB)	0.01	0.029	ND	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	<LOQ	<LOQ	<LOQ	<LOQ
Cannabidiphorol (CBDP)	0.016	0.049	ND	ND	ND	ND
exo-THC (exo-THC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.092	0.307	ND	ND	ND	ND
Δ8-tetrahydrocannabinol (Δ8-THC)	0.044	0.16	<LOQ	<LOQ	<LOQ	<LOQ
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.8	ND	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	ND	ND	ND	ND
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.8	ND	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	<LOQ	<LOQ	<LOQ	<LOQ
Δ9-Tetrahydrocannabihexol (Δ9-THCH)	0.02	0.061	ND	ND	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND	ND
9(S)-Hexahydrocannabinolic Acid (9(S)-HHCa)	0.063	0.065	ND	ND	ND	ND
9(R)-Hexahydrocannabinolic Acid (9(R)-HHCa)	0.191	0.196	ND	ND	ND	ND
Δ9-Tetrahydrocannabiphorol (Δ9-THCP)	0.017	0.8	ND	ND	ND	ND
Δ8-Tetrahydrocannabiphorol (Δ8-THCP)	0.041	0.8	ND	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND	ND
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.8	ND	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND	ND	ND
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.8	ND	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.015	0.045	ND	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.021	0.062	ND	ND	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			ND	ND	ND	ND
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			ND	ND	ND	ND
Total CBD (CBDa * 0.877 + CBD)			ND	ND	ND	ND
Total CBG (CBGa * 0.877 + CBG)			ND	ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND	ND
Total Cannabinoids Analyzed			ND	ND	ND	ND

4AD - 4AD Tryptamines

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-4AD
The expanded Uncertainty of the 4AD Tryptamines analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Mescaline (MESC)	0.19	0.584	ND	ND	ND	ND
N-methyl Tryptamine (NMT)	0.004	0.013	ND	ND	ND	ND
4-Hydroxy-MET (4-HO-MET)	0.013	0.04	ND	ND	ND	ND
n,n Dimethyltryptamine (DMT)	0.015	0.048	ND	ND	ND	ND
Psilacetin (PSLA)	0.015	0.044	ND	ND	ND	ND
4-Hydroxy-DET (4-HO-DET)	0.014	0.042	ND	ND	ND	ND

4-Acetoxy-MET (4-AcO-MET)	0.018	0.053	ND	ND	ND	ND
4-Acetoxy-DET (4-AcO-DET)	0.004	0.011	ND	ND	ND	ND
4-Bromo-DMP (2C-B)	0.19	0.576	ND	ND	ND	ND

TRY - Tryptamine

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-TRY
The expanded Uncertainty of the Tryptamine analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Norbaeocystin (NORB)	0.01	0.029	ND	ND	ND	ND
Baeocystin (BAEO)	0.01	0.029	ND	ND	ND	ND
Aeruginascin (AERU)	0.007	0.022	ND	ND	ND	ND
Norpsilocin (NORP)	0.003	0.009	ND	ND	ND	ND

PSY - Psilocybin & Psilocin

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-PSY
The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately ± 7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Psilocybin (PSCY)	0.007	0.019	ND	ND	ND	ND
Psilocin (PSCI)	0.003	0.009	ND	ND	ND	ND

UI Unidentified
ND Not Detected
N/A Not Applicable
NT Not Reported
LOD Limit of Detection
LOQ Limit of Quantification
<LOQ Detected
>ULOL Above upper limit of linearity
CFU/g Colony Forming Units per 1 gram
TNTC Too Numerous to Count



Coa_pjla_testing
(http://www.pjllabs.com)
Acc. #85368
(https://www.dropbox.com/scl/fi/3qeqn2se34ulpw8lm13ui/85368.pdf?rlkey=nviqubdnfhk1v1f6rx32mew63u&st=8wa4rbwv&dl=0)

DEA license: RP0611043
ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify.



Authorized Signature
Brandon_starr
Brandon Starr, Quality Assurance Manager
Tue, 04 Nov 2025 07:42:00 -0800



Pharmware_logo_simp
(https://pharmware.net)

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368

PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.